Наукова електронна бібліотека
періодичних видань НАН України
періодичних видань НАН України
The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
Репозиторій DSpace/Manakin
JavaScript is disabled for your browser. Some features of this site may not work without it.
The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
Тема:
Original contributions
Посилання:
The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells / A. Matveeva, L. Kovalevska, I. Kholodnyuk, T. Ivanivskaya, E. Kashuba // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 286–290. — Бібліогр.: 26 назв. — англ.
Підтримка:
We thank Professor Danylo Gluzman (R.E. Kavetsky IEPOR of NAS of Ukraine) for the fruitful discussions over this manuscript. This work was supported by the Swedish Cancer Society, by matching grants from the Concern Foundation (Los Angeles, USA) and the Cancer Research Institute (New York, USA), and by the Academy of Science of Ukraine (grant No. 0112U002192).
Дата:
2017
Переглядів:
866
Завантажень:
374
Анотація:
Aim: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover molecular details underlying CLL cell genesis. Objects and Methods: The study was conducted on peripheral blood samples of patients with CLL using the following methods: RNA isolation, analysis of expression of transcription factors using RT2 profiler assay, bioinformatics analysis of publicly available data bases on expression. Results: We have shown that the TGFB — SMAD canonical pathway is not active in CLL cells. SMAD-responsive genes, such as BCL2L1 (BCL-XL), CCND2 (Cyclin D2), and MYC, are down-regulated in CLL cells compared with peripheral blood B cells of healthy donors. Conclusions: The TGFB-mediated signaling is not active in CLL cells due to low (or absent) expression of SMAD1, -4, -5, -9, and ATF-3. Expression and phosphorylation status of SMAD2 and -3 should be further elucidated in the future studies.
